2025年第一天,李嘉诚的商业帝国,就进账45亿元。 1月1日,由李家控股的和黄医药发出公告,将出售子公司上海和黄药业45%的股权。接盘方是合资股东上海医药,及其联合方金浦健服。 交易完成后,上海医药将控股上海和黄药业,持有60%股权。 曾经,李嘉诚把中药视为和记黄埔第六大支柱产业,现在则将创新药视为圭臬。 “一边是中药,一边是西药,对资本市场来说,两边的价值很难在一个估值逻辑里体现。”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.